Modernizing the Global Postal System: Zonos Selected by the Universal Postal Union (UPU) to Power Enhanced Compliance, Processing Speed, and Transparency for Posts Worldwide
4.9.2024 17:00:00 EEST | Business Wire | Press release
In a groundbreaking move to address the dual challenges of evolving compliance regulations and increasing consumer expectations for swift, efficient deliveries, Zonos, the leader in cross-border technology solutions, has been selected by the Universal Postal Union (UPU) for a strategic initiative. The UPU is a United Nations specialized agency that facilitates international postal cooperation through its universal network of modern postal services. By leveraging Zonos' cutting-edge API technology to enhance the accuracy and processing speed of data transmitted through the UPU's Customs Declaration System (CDS), this effort is poised to transform the global postal ecosystem. This initiative aims to empower postal operators with technology to mitigate delays caused by inadequate or incomplete data, thereby improving operational efficiency, ensuring compliance, and significantly enhancing the delivery experience for consumers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904490189/en/
The international DDP shipping model allows parcels to ship with duties, taxes, and fees prepaid, making it easy for packages to move through customs. (Graphic: Business Wire)
Bridging the Technological Divide for Postal Operators Worldwide
This partnership specifically targets the technological challenges faced by postal operators around the globe. Many of these entities struggle to compete in an increasingly digital and data-driven landscape due to their limited ability to accurately and rapidly transmit electronic advanced data (EAD). This deficiency places them at a competitive disadvantage and contributes to significant delays in the international customs clearance process.
Zonos' innovative API technology offers a scalable and adaptable technology solution to these challenges, facilitating real-time, accurate data collection that meets the rigorous requirements of modern customs and security regulations that require detailed shipment information including good descriptions, harmonized codes, and accurate values for general or regional (such as ICS2) EAD regulations. The improved data quality addresses regulatory and safety concerns about the contents of packages for global customs operations.
Transitioning to a Delivered Duty Paid (DDP) Model
A significant goal of this collaboration is to transition towards a DDP model in response to market demand for more transparent and efficient customs processes. This initiative supports the UPU's Article 18-004 (Items for delivery free of charges and fees) by developing a robust DDP solution, facilitating smoother and faster cross-border mail and parcel deliveries. By enabling posts to calculate and collect duties and taxes at the point of sale, this model eliminates surprise costs for consumers and enhances the overall international mailing and delivery experience.
Enhancing Consumer Experience through Efficiency and Reliability
The UPU-Zonos initiative emphasizes improving the delivery experience for consumers worldwide. By streamlining the data collection process, the partnership aims to expedite customs clearance and reduce the time packages spend in transit to meet the consumer demand for speed. It also aims to enhance the reliability and predictability of international deliveries, fostering greater trust in the global postal system.
A Unified Vision for the Future of International Postal Services
The shared commitment of the UPU and Zonos to leveraging technology for the betterment of the global postal ecosystem is at the heart of this initiative. Clint Reid, CEO of Zonos, echoed this sentiment, highlighting the transformative potential of the collaboration: "Together, we are not just addressing immediate challenges; we are paving the way for a future where international postal services are more secure, efficient, and transparent for all."
About Zonos
Zonos is a leader in technology innovation for international commerce, simplifying cross-border trade with its comprehensive suite of solutions. Focused on compliance, classification, and transparent cost calculation, Zonos empowers businesses and postal operators to expand their global reach effortlessly, making international trade more accessible and transparent.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904490189/en/
Contacts
Jennifer Meads, Head of Marketing at Zonos
media@zonos.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release
Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 08:09:00 EEST | Press release
LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through centers in Romania and Portugal. This would create a more diversified portfolio for LTM – expanding its scale in Europe and Australia, enhancing its position in regulated and high-growth verticals through marquee customer relationships. The deal would augment LTM’s global AI-centric capabilities with local domain and near-shore expertise crucial for delivering digital an
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 08:00:00 EEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom